Treatment of pruritic diseases with topical calcineurin inhibitors

Therapeutics and Clinical Risk Management

Volumn 2, Issue 2, 2006, Pages 213-218

  Ständer, Sonja ^a   Schürmeyer Horst, Funda ^a   Luger, Thomas A ^a   Weisshaar, Elke ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Itch; Pimecrolimus; Pruritus; Tacrolimus; Vanilloid receptor

Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; TACROLIMUS;

ADULT; AGED; APPLICATION SITE BURNING; ARTICLE; CLINICAL ARTICLE; DERMATITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LICHEN SCLEROSUS ET ATROPHICUS; MALE; PRURIGO; PRURITUS; ROSACEA;

EID: 33646544164     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.2.213     Document Type: Article

References (27)

1. Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz C, et al. 2005. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br J Dermatol, 152:808-9.
2. Banky JP, Sheridan AT, Storer EL, et al. 2004. Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch Dermatol, 140:794-6.
3. Böhm M, Frieling U, Luger TA, et al. 2003. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol, 139:922-4.
4. Bornhövd EC, Burgdorf WH, Wollenberg A. 2002. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs, 3:708-12.
5. Caterina MJ, Schumacher MA, Tominaga M, et al. 1997. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature, 389:816-24.
6. Cherill R, Tofte S, MacNaul R, et al. 2000. SDZ ASM 981 1% cream is effective in the treatment of chronic irritant hand dermatitis. J Eur Acad Dermatol Venereol, 14(Suppl 1):128.
7. Choi CJ, Nghiem P. 2001. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol, 137:1202-6.
8. Duque MI, Yosipovitch G, Fleischer AB Jr, et al. 2005. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol, 52:519-21.
9. Eichmann AR. 2005. Dermatoses of the male genital area. Dermatology, 210:150-6.
10. Goldman D. 2001. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol, 44:995-8.
11. Greaves MW, Khalifa N. 2004. Itch: more than skin deep. Int Arch Allergy Immunol, 135:166-72.
12. Kuypers DR, Claes K, Evenepoel P, et al. 2004. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant, 19:1895-901.
13. Meurer M, Fölster-Holst R, Wozel G, et al. 2002. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology, 205:271-7.
14. Pauli-Magnus C, Klumpp S, Alscher DM, et al. 2000. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int, 20:802-3.
15. Reitamo S, Van Leent EJ, Ho V, et al. 2002. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol, 109:539-46.
16. Schmelz M. 2002. Itch - mediators and mechanisms. J Dermatol Sci, 28:91-6.
17. Senba E, Katanosaka K, Yajima H, et al. 2004. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res, 50:257-62.
18. Simpson D, Noble S. 2005. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs, 65:827-58.
19. Ständer S, Luger T, Metze D. 2001. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol, 44:471-8.
20. Ständer S, Gunzer M, Metze D, et al. 2002. Localization of mu-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept, 110:75-83.
21. Ständer S, Steinhoff M, Ständer H, et al. 2003. Morphological evidence of neuropeptide release and mast cell degranulation in tacrolimus (FK 506) and pimecrolimus (SDZASM 981) treated murine skin [abstract]. J Invest Dermatol, 121:0912.
22. Ständer S, Steinhoff M, Schmelz M, et al. 2003. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol, 139:1463-70.
23. Ständer S, Luger TA. 2003. Antipruritic effects of pimecrolimus and tacrolimus. Hautarzt, 54:413-17.
24. Ständer S, Moormann C, Schumacher M, et al. 2004. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol, 13:129-39.
25. Ständer S, Schmelz M, Metze D, et al. 2005. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci, 38:177-88.
26. Weisshaar E, Kucenic MJ, Fleischer AB Jr. 2003. Pruritus: A review. Acta Derm Venereol Suppl (Stockh), 213:5-32.
27. Welsh B, Howard A, Cook K. 2004. Vulval itch. Aust Fam Physician, 33:505-10.